Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma

Fig. 3

HDAC and Akt inhibitor treatment can overcome c-Myc upregulation by lenalidomide in CRBN-deficient cells. a-b Western blot validation of the effects of lenalidomide (Len) on CRBN-deficient cells. c-Myc expression could not be detected in OPM-2 CRBN sh#395 cells exposed to the control drug and Len 10 μM. c-d Validation of the effects of Len on control H929 or OPM-2 cells via western blot analysis. e-f RPMI8226 and H929 cell lysates treated with ACY-1215 and/or afuresertib were immunoblotted with the indicated antibodies (against GSK-3, p-GSK-3, c-Myc, and actin). g Myc mRNA levels in RPMI8226 cells treated with ACY-1215. (**p < 0.01) h RPMI8226 cell lysates treated with ACY-1215 and/or afuresertib were immunoblotted with indicated antibodies (against caspase-3, cleaved caspase-3, caspase-7, cleaved caspase-7, actin)

Back to article page